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We describe a novel cancer diagnostic method based on plasma denaturation 
profiles obtained by a non-conventional use of Differential Scanning Fluorimetry. We 
show that 84 glioma patients and 63 healthy controls can be automatically classified using 
denaturation profiles with the help of machine learning algorithms with 92% accuracy. 
Proposed high throughput workflow can be applied to any type of cancer and could 





Diffuse gliomas are the most frequent and aggressive primary brain tumors in 
adults. Currently, no curative treatment is available despite the association of surgical 
resection, radiotherapy and chemotherapy as first-line treatment 1. Another major 
challenge in glioma patient management is obtaining timely and precise histological and 
molecular characterization of the tumor in order to establish diagnosis and orient 
treatment. However, biopsies of these tumors are often impossible due to their deep or 
diffuse location, or due to patient comorbidities. In these cases, treatment is chosen 
based on MRI neuro-imaging characteristics that are often insufficient. More efficient 
ways to follow patients are also needed. Indeed, the evaluation of patients under 
treatment is currently based on MRI, steroid dose and clinical examination, which are 
often difficult to interpret after radiotherapy, anti-angiogenic therapy or immunotherapy 
2,3. Finally, an accurate and timely detection of the disease recurrence is crucial to 
optimize the therapeutic options and to improve patients’ treatment and quality of life. 
Thus, there is an urgent need in the neuro-oncology field to design new easy-to-use 
methods that are less invasive than histological examination and more efficient than 
neuroimaging in order to help patient diagnosis and to follow disease progression. 
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We have previously shown that despite the blood-brain barrier, the presence of 
glioblastoma induces changes in patients’ plasma that can be detected by Differential 
Scanning Calorimetry (DSC) 4,5. We now describe a novel method for high-throughput 
plasma profiling by repurposing another fundamental research method: nanoDSF 
(Differential Scanning Fluorimetry). NanoDSF, which was originally designed to study 
protein thermostability 6,7, is based on the modifications of the intrinsic fluorescence of 
the macromolecules upon their thermal denaturation. In this study we applied nanoDSF 
to analyze the plasma of patients affected by glioma and compared the obtained 
denaturation profiles to that of healthy individuals.  
We conducted this study on a bicentric cohort of 84 glioma patients with a median 
age of 49.3 years (range, 19.6 - 77.5). Twenty-two patients (26%) presented with a 1p/19q 
codeleted IDH mutated oligodendroglioma, 25 patients (31%) with an IDH mutated 
astrocytoma and 37 patients (43%) with an IDH wild-type astrocytoma (see Table 1 for 
more detailed patient characteristics). Plasma samples from this cohort and from the 63 
healthy controls were loaded to 24-capillary chips and then scanned using nanoDSF 
Prometheus NT.Plex instrument (Nanotemper) in order to obtain the denaturation profiles 
in the range from 15 to 95°C. Raw data were exported into datasets that contained all of 
the nanoDSF outputs: fluorescence at 330 and 350 nm (F330 and F350), the ratio of 
these values (F330/F350) as well as absorbance at 350 nm (A350). The first derivatives 
of F330/F350 were plotted to visualize denaturation (Figure 1). As seen from this figure, 
the mean denaturation profile of the glioma patients’ plasma was drastically different from 
that of healthy individuals.  
The observed difference in the plasma denaturation profiles between the glioma 
and the healthy samples can be explained by the variation in thermal stability of the 
plasma constituents. Indeed, the plasma denaturation profiles correspond to the 
cumulative sum of those from the most abundant plasma proteins 8. Since the thermal 
denaturation profile of a protein is an intrinsic property dependent on its structure, 
modifications such as mutation, post translational modifications, or ligand binding can 
significantly impact this profile. Similarly to results obtained with DSC 5,8, we observed 
low variability in nanoDSF denaturation profiles within controls, regardless of sex or age 
of the individuals. This can be explained by the fact that the composition of many biofluids 
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such as plasma, serum, cerebrospinal fluid, is meticulously maintained by the organism, 
thus resulting in a reproducible denaturation profile. Such healthy plasma equilibrium is 
altered in glioma patients, leading to the emergence of a different glioma profile. Even 
though further studies are needed to identify the molecular basis of plasma changes in 
glioma patients, observed differences can be used for diagnostic purposes.  
In order to differentiate between the denaturation profiles of healthy individuals and 
glioma patients, we set out to design an automated way to classify the obtained profiles 
using an Artificial Intelligence (AI) approach. Moreover, automation is needed for future 
applications of this approach to much larger scale analysis in clinics as well as to detect 
possible subtle differences between subgroups of samples. We tested several machine 
learning (ML) algorithms 9 on the raw data: the classical Logistic Regression (LR), the 
often well-performing Support Vector Machine (SVM), the well-known Neural Networks 
(NN), and two different ensemble methods: Random Forest (RF) and Adaptive Boosting 
(AdaBoost). These algorithms were evaluated using a leave-one-out approach where 
each datum is used once as a test, while the others are used to train the automatic 
classifiers: the obtained values were thus averages on as many experiments as there are 
data. The three nanoDSF outputs (F330, F350 and A350) were tested independently and 
in combination as input for these artificial intelligence algorithms. Table 2 shows the 
results obtained with the five ML algorithms (LR, SVM, NN, RG and AdaBoost) using the 
settings allowing the best observed performance on our 147 samples (84 patients and 63 
controls). NN and AdaBoost algorithms had the best accuracy of above 92%, while all 
others achieved around 90% of correct classification. LR algorithm provided the lowest 
number of false positives (four healthy individuals were wrongly classified as glioma 
patients), while AdaBoost was better at reducing the number of false negatives (five 
glioma patients classified as healthy). The two algorithms with highest accuracy (NN and 
AdaBoost) had closely related small numbers of the two error types (false positives: 5 
and 6 respectively, false negatives: 6 and 5 respectively). When the algorithm allowed it, 
we also tested its version that focuses on minimizing the number of false negatives, in 
order to decrease the possibility of missing the diagnosis of glioma that could have 
devastating consequences given the rapidly developing nature of this disease. As seen 
from the Table 2, the false negative focussing version of the SVM algorithm (fnf-SVM) 
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maintained the same level of overall accuracy as the original SVM (87.07% of correct 
classification) while obtaining just one false negative (corresponding to 1.19% of glioma 
patients mis-classified by this algorithm). Taken together, our results show that detection 
of glioma based on the denaturation profile of plasma can be efficiently automated. 
Moreover, combining high-throughput nanoDSF and automated data treatment by 
machine learning makes our approach compatible with large-scale applications in clinics 
for cancer detection using a simple blood test. 
Detection of cancers by a minimally invasive blood test, or “liquid biopsy”, has been 
a long-thought goal in the field. A number of different cancer detection methods have 
been tested over the past ten years, which are based on Differential Scanning Calorimetry 
(DSC) 8, infrared technology (ATR-FTIR) 10 as well as on the detection and isolation of 
cell-free nucleic acids, extracellular vesicles and circulating tumor cells 11–14. Among 
these, many pilot studies have previously tested DSC of biofluids as a one-step and low 
cost approach for diagnosis of a great number of diseases including several types of 
cancers 8,15,16, raising hopes about creation of a unique pan-cancer diagnostic tool. 
However, despite the efforts invested in developing this approach, technical restrictions 
and low throughput of DSC instruments made them impossible to be transferred for wide 
use in clinics. In our study, we describe a major technical breakthrough allowing us to 
overcome these obstacles. Indeed, our approach using the nanoDSF instrument requires 
minimal quantity of plasma, no need for sample preparation, and allows much faster 
sample handling due to disposable capillaries and high-powered fully automated data 
analysis using machine learning algorithms. Compared to classical DSC, our method 
provides a significant increase in throughput and reproducibility while decreasing the 
possibility of technical error.  
In conclusion, our proof-of-concept study demonstrates the possibility to 
automatically distinguish glioma patients from healthy controls by a simple blood test, 
using a novel technology that combines differential scanning fluorimetry and machine 
learning algorithms. We propose that plasma profiling using denaturation signatures by 
nanoDSF can be used to develop low cost and high throughput diagnostic methods for 
cancers and human disease in general. 
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FACTORS N % 
Age (median, min-max) 49.3 ( 19.6 - 77.5) 
Gender (Men/women) 45/39 54/46 
KPS (median, min-max) 80 (50 - 100) 
    50 1 1 
    60 10 13 
    70 17 21 
    80 23 29 
    90 20 25 
    100 9 11 
Steroids 51 64 
Histology 
Oligodendroglioma 
    Grade II 2 2 
    Grade III 20 24 
Astrocytoma IDHmut 
    Grade II 3 4 
    Grade III 19 23 
    Grade IV 3 4 
Astrocytoma IDHwt 
    Grade II 7 8 
    Grade III 11 13 
    Grade IV 19 22 
Surgery 
    Gross total resection 33 41 
    Partial resection 48 59 
Adjuvant treatment 
    Radiotherapy alone 10 12 
    Chemotherapy alone 12 14 
    Radiotherapy + chemotherapy 57 68 
    None 5 6 




        
 Original algorithms  FN minimized 
Algorithm LR SVM NN RF AdaBoost fnf-SVM 
Accuracy 89.80 87.07 92.52 89.12 92.52 87.07 
False 
positives 4 13 5 8 6 18 
False 
negatives 11 6 6 8 5 1 
 





Figure 1. Means of the first derivatives of the ratio F330/F350. The red curve 
corresponds to glioma patients while the green one is the one of the controls. The color 
regions graphically shows the variability of the data by indicating the confidence interval 
at 99%.  
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Methods section  
Patients 
Patient cohort consisted of 51 patients included at La Timone Hospital (Marseille) 
from June 2009 to February 2017 and 33 patients included at La Pitié Salpétrière Hospital 
(Paris) from November 2008 to September 2016. Eligible patients included were those 
aged 18 years or older with newly diagnosed glioma for whom plasma samples were 
available at the time of diagnosis, before adjuvant treatment. Clinical evaluations were 
performed every cycle and imaging evaluations were performed every two cycles. 
Treatment responses and disease progression were reviewed using the RANO criteria 3. 
All patients provided written informed consent in accordance with institutional, national 
guidelines and the Declaration of Helsinki.  
Plasma samples 
Blood samples from this cohort and from 63 healthy controls were collected into 
EDTA tubes, separated by centrifugation (2000g, 10 minutes, 20°C, twice) within 30 
minutes and then stored at - 80°C. No other specific purification step was added in order 
not to perturb the interactome or alter the chemical state of plasma proteins. Before 
nanoDSF analysis, samples were thawed rapidly at 37°C, centrifuged and loaded on a 
10 μL capillary. 
Sample analysis by nanoDSF 
Plasma samples were loaded to 10 μL capillaries and scanned using nanoDSF 
Prometheus NT.Plex instrument (Nanotemper) at 5% of laser power and 1°C/min heating 
rate to obtain denaturation profiles in the range from 15 to 95°C. The machine can analyse 
24 samples at once: we carefully mixed patients and controls to avoid any batch effect. 
Raw data were exported into datasets that contained all the nanoDSF outputs : 
fluorescence at 330 and 350 nm (F330 and F350) as well as the ratio of these values 
(F330/F350) and absorbance at 350 nm (A350). 
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Algorithm trainings 
The code used was written in Python. The data preparation was done using the 
pandas library (https://pandas.pydata.org) while the machine learning algorithms were 
run using the scikit-learn toolbox (https://scikit-learn.org). Raw data from the nanoDSF 
instrument (F330, F350 and A350) were interpolated using InterpolatedUnivariateSpline 
from the scipy.interpolate module in order to ensure the same temperature alignment for 
all data. The different tested implementations are: (1) LogisticRegression from the 
linear_model module with parameter max_iter sets to 1000; (2) SVC from the svm module 
with the following combination of parameters: kernel=’poly’, gamma=’auto’, C=1, degree 
between 1 and 3; kernel=’rbf’, C=1, gamma within [0.001, 0.01, 0.1, 1, 10]. The fnf-SVM 
results were obtained using SVC with the same parameters except for class_weight that 
was set to {0:1, 1:100} (instead of the default None value); (3) MLPClassifier from the 
neural_network module with different architecture (reported results correspond to 3 
hidden layers of 750, 200, 50, respectively), max_iter was fixed to 5000 and 
learning_rate='adaptive'; (4) RandomForestClassifier from the ensemble module with 
parameter n_estimators fixed to 500; (5) AdaBoostClassifier from the module ensemble 
with a DecisionTreeClassifier from the module tree as weak classifier (parameter 
base_estimator) with max_depth taken between 1 and 3, n_estimators set to 100. All 
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